Delivery Order SPE2DB22D3501-SPE2DB25FXF08
- Not listed
- The Defense Logistics Agency awarded a $24,781.68 delivery order to AmerisourceBergen Drug Corp for the supply of Dasatinib 100 mg tablets in quantities of 30, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger contract vehicle with the agency. The pharmaceutical product will be delivered to the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $8,260.56 to AmerisourceBergen Drug Corp for the supply of Dasatinib 100 mg tablets (30-count units) with a firm fixed price structure. This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was competitively made with no set-aside designation, and delivery is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dasatinib 80 mg tablets (30-count packaging) under a firm fixed-price contract valued at $82,393.53. The order is set to be completed by July 29, 2025, with fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued against AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $9,193.03 to AmerisourceBergen Drug Corp for Dasatinib 50 mg tablets (60-count supply) on August 11, 2025, with a completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing...
- This delivery order, awarded on July 24, 2025, represents a $43,339.66 firm fixed-price contract for 60-count bottles of Dasatinib 50 mg tablets to be delivered to Conshohocken, Pennsylvania. The Defense Logistics Agency awarded this non-competitive delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement. The award is expected to be completed by July 25, 2025, reflecting a rapid fulfillment timeline typical of...
- This delivery order awards AmerisourceBergen Drug Corp $6,924.66 for the supply of Dasatinib 50 mg tablets (60-count units) under a firm fixed-price contract with the Defense Logistics Agency's Medical Supply Chain. The award, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a non-set-aside competitive procurement. The place of performance is listed as the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a $30,587.03 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60-count bottles of Dasatinib 50 mg tablets, with an ultimate completion date of July 29, 2025. This non-set-aside contract was competitively awarded on July 28, 2025, with performance occurring at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor,...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide 60 tablets of the medication Dasatinib 50 mg. The contract has a ceiling value of $40,984.03 and a completion date of July 2, 2025. There is no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor and there is no information provided about any subcontractors. This delivery...
- This federal contract award, valued at $5,456.86, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4568096600 - Dasatinib 20 mg Tablet 60s, a prescription medication, with a completion date of May 2, 2025. The contract is a Firm Fixed Price Delivery Order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999.00...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $73,214.61 firm fixed-price delivery order is for the supply of DASATINIB 80 MG TABLET 30S, a prescription medication. The contract has an ultimate completion date of February 28, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXF08Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dasatinib 140 mg tablets in a quantity of 30 units, with a contract ceiling value of $3,744.14. This competitively awarded, firm fixed-price delivery order was established on September 8, 2025, with an ultimate completion date of September 9, 2025. The contract represents a child award under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and extends through December 2026. AmerisourceBergen's primary place of performance is located in Conshohocken, Pennsylvania. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The parent IDC vehicle provides comprehensive global pharmaceutical support, enabling the company to supply a wide range of products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. Dasatinib, a tyrosine kinase inhibitor used in oncology treatment, reflects the company's role in delivering specialized pharmaceutical commodities to support Defense Health Agency operations and other government healthcare systems. This delivery order carries no set-aside designation and was awarded through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 9/8/25 |